Fatty alcohol esters of hydroxycarboxylic acids
Described herein are compositions (e.g., a pharmaceutical composition) and compounds of formula I, methods of making compounds of formula (I) and their use in the treatment and/or prevention of diseases and disorders.
1. A pharmaceutical composition comprising a compound of formula (I):
wherein
R 1 is a C 12 alkyl;
n is an integer from 4 to 10; and
R 2 is hydrogen, alkyl, aryl, heteroaryl, or heterocyclyl;
or a pharmaceutically acceptable salt thereof.
2. The pharmaceutical composition of claim 1 , wherein R 2 is alkyl.
3. The pharmaceutical composition of claim 2 , wherein R 2 is C 1-4 alkyl.
4. The pharmaceutical composition of claim 1 , wherein R 2 is aryl.
5. The pharmaceutical composition of claim 2 , wherein R 2 is aralkyl.
6. The pharmaceutical composition of claim 1 , wherein when R 2 is not hydrogen, the compound of formula (I) is a racemic mixture of a compound of formula (I).
7. The pharmaceutical composition of claim 1 , wherein when R 2 is not hydrogen, the compound of formula (I) is at least 10% enantiomeric excess of the R stereoisomer.
8. The pharmaceutical composition of claim 7 , wherein when R 2 is not hydrogen, the compounds of formula (I) is at least 50% enantiomeric excess of the R stereoisomer.
9. The pharmaceutical composition of claim 8 , wherein when R 2 is not hydrogen, the compound of formula (I) is at least 75% enantiomeric excess of the R stereoisomer.
10. The pharmaceutical composition of claim 9 , wherein when R 2 is not hydrogen, the compound of formula (I) is at least 85% enantiomeric excess of the R stereoisomer.
11. The pharmaceutical composition of claim 10 , wherein when R 2 is not hydrogen, the compound of formula (I) is at least 90% enantiomeric excess of the R stereoisomer.
12. The pharmaceutical composition of claim 11 , wherein when R 2 is not hydrogen, the compound of formula (I) is at least 95% enantiomeric excess of the R stereoisomer.
13. The pharmaceutical composition of claim 12 , wherein when R 2 is not hydrogen, the compound of formula (I) is least 97% enantiomeric excess of the R stereoisomer.
14. The pharmaceutical composition of claim 13 , wherein when R 2 is not hydrogen, the compound of formula (I) is at least 99% enantiomeric excess of the R stereoisomer.
15. The pharmaceutical composition of claim 1 , wherein when R 2 is not hydrogen, the compound of formula (I) is at least 10% enantiomeric excess of the S stereoisomer.
16. The pharmaceutical composition of claim 1 , wherein when R 2 is not hydrogen, the compound of formula (I) is at least 50% enantiomeric excess of the S stereoisomer.
17. The pharmaceutical composition of claim 16 , wherein when R 2 is not hydrogen, the compound of formula (I) is at least 75% enantiomeric excess of the S stereoisomer.
18. The pharmaceutical composition of claim 17 , wherein when R 2 is not hydrogen, the compound of formula (I) is at least 85% enantiomeric excess of the S stereoisomer.
19. The pharmaceutical composition of claim 18 , wherein when R 2 is not hydrogen, the compound of formula (I) is at least 90% enantiomeric excess of the S stereoisomer.
20. The pharmaceutical composition of claim 19 , wherein when R 2 is not hydrogen, the compound of formula (I) is at least 95% enantiomeric excess of the S stereoisomer.
21. The pharmaceutical composition of claim 20 , wherein when R 2 is not hydrogen, the compound of formula (I) is at least 97% enantiomeric excess of the S stereoisomer.
22. The pharmaceutical composition of claim 21 , wherein when R 2 is not hydrogen, the compound of formula (I) is at least 99% enantiomeric excess of the S stereoisomer.
23. The pharmaceutical composition of claim 1 , wherein the compound of formula (I) is represented by the following formula:
24. The pharmaceutical composition of claim 1 , wherein the compound of formula (I) is represented by the following formula:
25. The pharmaceutical composition of claim 1 , wherein the compound of formula (I) is represented by the following formula:
26. A pharmaceutical composition comprising a compound of formula (I):
wherein
R 1 is a C 8-35 alkyl;
n is an integer from 4 to 10; and
R 2 is hydrogen, alkyl, aryl, heteroaryl, or heterocyclyl;
or a pharmaceutically acceptable salt thereof.
27. The pharmaceutical composition of claim 26 , wherein R 1 is a C 8-25 alkyl group.
28. The pharmaceutical composition of claim 27 , wherein R 1 is a C 10-20 alkyl group.
29. The pharmaceutical composition of claim 28 , wherein R 1 is a C 10-15 alkyl group.
30. The pharmaceutical composition of claim 29 , wherein R 1 is a C 12 alkyl group.
31. The pharmaceutical composition of claim 26 , wherein R 2 is alkyl.
32. The pharmaceutical composition of claim 31 , wherein R 2 is C 1-4 alkyl.
33. The pharmaceutical composition of claim 26 , wherein R 2 is aryl.
34. The pharmaceutical composition of claim 31 , wherein R 2 is aralkyl.
35. The pharmaceutical composition of claim 26 , wherein when R 2 is not hydrogen, the compound of formula (I) is a racemic mixture of a compound of formula (I).
36. The pharmaceutical composition of claim 26 , wherein when R 2 is not hydrogen, the compound of formula (I) is at least 10% enantiomeric excess of the R stereoisomer.
37. The pharmaceutical composition of claim 36 , wherein when R 2 is not hydrogen, the compounds of formula (I) is at least 50% enantiomeric excess of the R stereoisomer.
38. The pharmaceutical composition of claim 37 , wherein when R 2 is not hydrogen, the compound of formula (I) is at least 75% enantiomeric excess of the R stereoisomer.
39. The pharmaceutical composition of claim 38 , wherein when R 2 is not hydrogen, the compound of formula (I) is at least 85% enantiomeric excess of the R stereoisomer.
40. The pharmaceutical composition of claim 39 , wherein when R 2 is not hydrogen, the compound of formula (I) is at least 90% enantiomeric excess of the R stereoisomer.
41. The pharmaceutical composition of claim 40 , wherein when R 2 is not hydrogen, the compound of formula (I) is at least 95% enantiomeric excess of the R stereoisomer.
42. The pharmaceutical composition of claim 41 , wherein when R 2 is not hydrogen, the compound of formula (I) is least 97% enantiomeric excess of the R stereoisomer.
43. The pharmaceutical composition of claim 42 , wherein when R 2 is not hydrogen, the compound of formula (I) is at least 99% enantiomeric excess of the R stereoisomer.
44. The pharmaceutical composition of claim 26 , wherein when R 2 is not hydrogen, the compound of formula (I) is at least 10% enantiomeric excess of the S stereoisomer.
45. The pharmaceutical composition of claim 26 , wherein when R 2 is not hydrogen, the compound of formula (I) is at least 50% enantiomeric excess of the S stereoisomer.
46. The pharmaceutical composition of claim 45 , wherein when R 2 is not hydrogen, the compound of formula (I) is at least 75% enantiomeric excess of the S stereoisomer.
47. The pharmaceutical composition of claim 46 , wherein when R 2 is not hydrogen, the compound of formula (I) is at least 85% enantiomeric excess of the S stereoisomer.
48. The pharmaceutical composition of claim 47 , wherein when R 2 is not hydrogen, the compound of formula (I) is at least 90% enantiomeric excess of the S stereoisomer.
49. The pharmaceutical composition of claim 48 , wherein when R 2 is not hydrogen, the compound of formula (I) is at least 95% enantiomeric excess of the S stereoisomer.
50. The pharmaceutical composition of claim 49 , wherein when R 2 is not hydrogen, the compound of formula (I) is at least 97% enantiomeric excess of the S stereoisomer.
51. The pharmaceutical composition of claim 50 , wherein when R 2 is not hydrogen, the compound of formula (I) is at least 99% enantiomeric excess of the S stereoisomer.
52. The pharmaceutical composition of claim 26 , wherein the compound of formula (I) is represented by the following formula:
53. The pharmaceutical composition of claim 26 , wherein the compound of formula (I) is represented by the following formula:
54. The pharmaceutical composition of claim 26 , wherein the compound of formula (I) is represented by the following formula: